AMSTERDAM--(BUSINESS WIRE)--Pulmonx has just announced final results of its Chartis multi-centre study 1, presented today at the European Respiratory Society’s 2011 Congress. This definitive data confirms that use of the Chartis® Pulmonary Assessment System to plan Zephyr® valve treatments is the key to successful EBV treatment of emphysema.
